Table 1.
Demographic and clinical characteristics of RA patients by treatment group.
| Variable | All Patients (n=93) | JAKi Group (n=36) | CTLA4-Ig Group (n=30) | TNFi Group (n=27) |
|---|---|---|---|---|
| Female, n (%) | 61 (66%) | 27 (75%) | 17 (57%) | 17 (63%) |
| Age, years, median (IQR) | 71 (66–78) | 69 (65–78) | 71 (67–78) | 73 (66–78) |
| RA duration, years, median (IQR) | 9 (3–15) | 9 (6–14) | 8 (2–14) | 8 (2–17) |
| RF positive, n (%) | 88 (95%) | 32 (89%) | 29 (97%) | 27 (100%) |
| ACPA positive, n (%) | 85 (91%) | 32 (89%) | 28 (93%) | 25 (93%) |
| Concomitant use of MTX, n (%) | 35 (38%) | 14 (39%) | 7 (23%) | 14 (52%) |
| Concomitant use of GC, n (%) | 51 (55%) | 22 (61%) | 20 (67%) | 9 (33%) |
| DAS28-ESR, median (IQR) | 4.85 (3.88–5.55) | 5.19 (4.39–5.93) | 4.90 (3.52–5.46) | 4.54 (3.40–5.18) |
| CT pattern, n | UIP 30, non-UIP 63 | UIP 6, non-UIP 30 | UIP 15, non-UIP 15 | UIP 9, non-UIP 18 |
| Extent of fibrotic lesions >10%, n (%) | 21 (23%) | 6 (17%) | 9 (30%) | 6 (22%) |
| CT score, median (IQR) | 122 (109–147) | 110 (106–132) | 126 (112–153) | 129 (114–145) |
ACPA, anti-citrullinated protein antibody; CT, computed tomography; CTLA4-Ig, T cell co-stimulation inhibitor; DAS28-ESR, Disease Activity Score based on a 28-joint count–erythrocyte sedimentation rate; GC, glucocorticoids; IQR, interquartile range; JAKi, Janus kinase inhibitor; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFi, tumor necrosis factor inhibitor; UIP, usual interstitial pneumonia.